白云山(00874.HK)治疗高胆固醇血症药物于中国上市申请获批

阿斯达克财经
07 Mar

白云山(00874.HK) 公布,其分公司白云山化学制药厂于近日,收到国家药监局签发的阿托伐他汀钙《化学原料药上市申请批准通知书》。
公告指,上述药物主要通过抑制HMGCoA还原酶的合成,从而抑制体内胆固醇的合成,降低血清低密度脂蛋白胆固醇、甘油三酯的含量。主要适应症为原发性高胆固醇血症、混合型高脂血症、高甘油三酯血症、纯合子家族性高胆固醇血症及防治动脉粥样硬化。
公司引述第三方数据指出,去年阿托伐他汀钙片在中国公立医院和零售药店的销售额为63.74亿元人民币。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-06 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10